For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…
Shanghai, July 24, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a…
This non-surgical revolutionary treatment has no side effects and higher survival rate, says Dr. Sandip Jhala, Interventional Specialist, Apollo Hospitals-Ahmedabad…